Expressions of interest
TRI is seeking Expressions of Interest from life science start up companies that are looking to take their research from laboratory discovery to application in the community.
About TRI
Located within the Princess Alexandria Hospital Campus, the Translational Research Institute (TRI) is a unique, Australian-first initiative of ‘bench to bedside’ medical research. TRI combines clinical and translational research to advance progress from laboratory discovery to application in the community.
This vision was conceived and brought to fruition by the clinicians and scientists of the four institutions who were its founding partners; The University of Queensland, Queensland University of Technology, Mater Medical Research Institute and Queensland Health.
The work conducted at TRI is translational research, a research process which involves teams of patients, clinicians and researchers working together to solve health challenges faster. The work is driven by the needs of patients, a question formed by a clinician and a solution sought by a scientist. While traditionally, clinicians and researchers worked separately, this improved method ensures patient needs are priority and that teams share knowledge which multiplies with every collaboration. These teams also create a feedback loop which is essential to the translational pathway. With the clinician and scientist working side by side with the patient, results are obvious immediately rather than via long reports which take time to read and interpret.
Project Description
[email protected] is being developed in response to market demand and aspiration from resident start-ups outgrowing or “scaling up” out of the original TRI and need to remain within its supportive environment as they continue their commercialisation journey. [email protected] will offer cGMP cleanrooms and a platform for advanced and small-scale drug and medtech manufacturing.
[email protected] has been developed to be a new facility where the size and scale of the user areas can increase subject to user/occupier demand and the space can be catered for generally commercial users that may have a specific need or desire to be located at PAH, within a growing medtech precinct.
[email protected]’s state-of-the-art research facilities make it the ideal location for companies exploring innovation in a wide range of health related industries that complement the scale-up ecosystem including:
- Biotechnology
- Vaccines
- Cell therapies
- Medical devices
- eHealth
- Artificial intelligence
- 3D Printing
- Small molecules
- Medical equipment design and assembly
- Robotics
- Industrial automation
Objectives
The aim of this Expressions of Interest exercise is to:
- Provide further communication of the Project and opportunity to potential users and occupiers.
- Assist TRI determine the level of market demand from end users;
- Provide interested parties with an opportunity to enter further dialog with TRI on their specific needs, timing and how the facility could enhance their research capabilities.
Timing
TRI requests Expressions of Interest are provided by Monday, 5 September 2022.
Confidentiality
Your responses to this Expression of Interest are confidential and TRI will take reasonable steps to ensure this (including by de-identifying the information). By submitting a response, you agree that TRI may use the de-identified information you provide for the Objectives listed above.
